These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9413086)

  • 21. Vaccines for preventing typhoid fever.
    Anwar E; Goldberg E; Fraser A; Acosta CJ; Paul M; Leibovici L
    Cochrane Database Syst Rev; 2014 Jan; (1):CD001261. PubMed ID: 24385413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of two WHO First International Standards for Vi polysaccharide from Citrobacter freundii and Salmonella enterica subspecies enterica serovar Typhi.
    Gao F; Swann C; Rigsby P; Rijpkema S; Lockyer K; Logan A; Bolgiano B;
    Biologicals; 2019 Jan; 57():34-45. PubMed ID: 30502020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide.
    Tacket CO; Pasetti MF; Sztein MB; Livio S; Levine MM
    J Infect Dis; 2004 Aug; 190(3):565-70. PubMed ID: 15243933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study.
    Mitra M; Shah N; Ghosh A; Chatterjee S; Kaur I; Bhattacharya N; Basu S
    Hum Vaccin Immunother; 2016 Apr; 12(4):939-45. PubMed ID: 26901576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistence of antibody titres three years after vaccination with Vi polysaccharide vaccine against typhoid fever.
    Tacket CO; Levine MM; Robbins JB
    Vaccine; 1988 Aug; 6(4):307-8. PubMed ID: 3188615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Experience with Vi typhoid capsular polysaccharide vaccine in the U.K.
    Arnold WS; Harcus AW; St Clair Roberts J; Ward AE
    J Infect; 1992 Jul; 25(1):63-6. PubMed ID: 1522324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children.
    Mai NL; Phan VB; Vo AH; Tran CT; Lin FY; Bryla DA; Chu C; Schiloach J; Robbins JB; Schneerson R; Szu SC
    N Engl J Med; 2003 Oct; 349(14):1390-1. PubMed ID: 14523155
    [No Abstract]   [Full Text] [Related]  

  • 28. Population impact of Vi capsular polysaccharide vaccine.
    Khan MI; Ochiai RL; Clemens JD
    Expert Rev Vaccines; 2010 May; 9(5):485-96. PubMed ID: 20450323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccination of active component US military personnel against Salmonella Typhi.
    Porter CK; Sorrell T; Mitra I; Riddle MS
    Vaccine; 2017 Mar; 35(14):1742-1748. PubMed ID: 28268075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vi capsular polysaccharide: Synthesis, virulence, and application.
    Hu X; Chen Z; Xiong K; Wang J; Rao X; Cong Y
    Crit Rev Microbiol; 2017 Aug; 43(4):440-452. PubMed ID: 27869515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isotypes of human vaccinal antibodies to the Vi capsular polysaccharide of Salmonella typhi.
    Brugier JC; Barra A; Schulz D; Preud'homme JL
    Int J Clin Lab Res; 1993; 23(1):38-41. PubMed ID: 8477090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization.
    Klugman KP; Koornhof HJ; Robbins JB; Le Cam NN
    Vaccine; 1996 Apr; 14(5):435-8. PubMed ID: 8735556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibodies to the Vi capsule of Salmonella Typhi in the serum of typhoid patients and healthy control subjects from a typhoid endemic region.
    House D; Ho VA; Diep TS; Chinh NT; Bay PV; Vinh H; Duc M; Parry CM; Dougan G; White NJ; Farrar JJ; Hien TT; Wain J
    J Infect Dev Ctries; 2008 Aug; 2(4):308-12. PubMed ID: 19741294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. S.Typhi derived OmpC peptide conjugated with Vi-polysaccharide evokes better immune response than free Vi-polysaccharide in mice.
    Haque S; Sengupta S; Gupta D; Bhan MK; Kumar R; Khan A; Jailkhani B
    Biologicals; 2019 Nov; 62():50-56. PubMed ID: 31606267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Typhoid Vi: a less reactogenic vaccine.
    Cumberland NS; St Clair Roberts J; Arnold WS; Patel RK; Bowker CH
    J Int Med Res; 1992 Jun; 20(3):247-53. PubMed ID: 1397669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Significance of Vi Negative Isolates of Salmonella Enterica Serovar Typhi.
    Haque A
    Adv Exp Med Biol; 2018; 1052():9-18. PubMed ID: 29785477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of purified Vi polysaccharide typhoid vaccine.
    Park JH; Hong JJ; Choi ES; Lee JW; Park JH
    J Vet Sci; 2002 Jun; 3(2):67-70. PubMed ID: 12441674
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India.
    Sur D; Ochiai RL; Bhattacharya SK; Ganguly NK; Ali M; Manna B; Dutta S; Donner A; Kanungo S; Park JK; Puri MK; Kim DR; Dutta D; Bhaduri B; Acosta CJ; Clemens JD
    N Engl J Med; 2009 Jul; 361(4):335-44. PubMed ID: 19625715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The capsular polysaccharide Vi from Salmonella typhi is a B1b antigen.
    Marshall JL; Flores-Langarica A; Kingsley RA; Hitchcock JR; Ross EA; López-Macías C; Lakey J; Martin LB; Toellner KM; MacLennan CA; MacLennan IC; Henderson IR; Dougan G; Cunningham AF
    J Immunol; 2012 Dec; 189(12):5527-32. PubMed ID: 23162127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An outbreak of typhoid fever, Xing-An County, People's Republic of China, 1999: estimation of the field effectiveness of Vi polysaccharide typhoid vaccine.
    Yang HH; Kilgore PE; Yang LH; Park JK; Pan YF; Kim Y; Lee YJ; Xu ZY; Clemens JD
    J Infect Dis; 2001 Jun; 183(12):1775-80. PubMed ID: 11372030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.